Uniqure NV (QURE) Stock: What Does the Chart Say Thursday?

The market has been high on Uniqure NV (QURE) stock recently. QURE gets a Bullish score from InvestorsObserver Stock Sentiment Indicator.

Uniqure NV has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on QURE!

See Full QURE Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With QURE Stock Today?

Uniqure NV (QURE) stock is down -8.36% while the S&P 500 has risen 0.16% as of 10:12 AM on Thursday, Feb 29. QURE is down -$0.56 from the previous closing price of $6.69 on volume of 199,156 shares. Over the past year the S&P 500 is up 27.91% while QURE is down -70.75%. QURE lost -$4.79 per share in the over the last 12 months.

More About Uniqure NV

uniQure NV is a gene therapy company. It develops treatment and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Click Here to get the full Stock Report for Uniqure NV stock.